SATURABLE PHARMACOKINETICS AND PACLITAXEL PHARMACODYNAMICS IN CHILDREN WITH SOLID TUMORS

被引:131
作者
SONNICHSEN, DS
HURWITZ, CA
PRATT, CB
SHUSTER, JJ
RELLING, MV
机构
[1] ST JUDE CHILDRENS RES HOSP, DEPT PHARMACEUT SCI, MEMPHIS, TN USA
[2] ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN USA
[3] UNIV TENNESSEE, CTR PEDIAT PHARMACOKINET & THERAPEUT, DEPT CLIN PHARM, MEMPHIS, TN USA
[4] UNIV FLORIDA, DEPT STAT, GAINESVILLE, FL 32611 USA
[5] PEDIAT ONCOL GRP, ST LOUIS, MO USA
关键词
D O I
10.1200/JCO.1994.12.3.532
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Our aim was to evaluate the pharmacokinetics and pharmacodynamics of paclitaxel (Taxol; Bristol-Myers Squibb Co, Princeton, NJ) in children, and to determine whether paclitaxel exhibited saturable pharmacokinetics. Patients and Methods: We evaluated the pharmacokinetics and pharmacodynamics of paclitaxel (200 to 420 mg/m2) administered as a 24-hour intravenous (IV) infusion in a phase I study of 30 pediatric patients (age, 2.3 to 22.8 years) with refractory solid tumors. Fourteen serial blood samples were obtained during and up to 48 hours after the infusion, and paclitaxel concentrations were measured by a high-performance liquid chromatography-UV (HPLC-UV) method. Four pharmacokinetic models were compared for their ability to describe the patients' data. Results: Paclitaxel disposition was not consistent with a first-order, two-compartment pharmacokinetic model. Rather, the majority of data sets were best described by a two-compartment model that incorporated both saturable tissue distribution and saturable elimination; a smaller number of patient data sets were best described by models that incorporated either saturable distribution or saturable elimination. Clearance was dose-dependent, with a median clearance at the lower dosages (< 400 mg/m2) of 161 mL/min/m2, and at the highest dosages (> 400 mg/m2) of 123 mL/min/m2 (P = .044). The duration that paclitaxel plasma concentrations exceeded 0.1 μmol/L was highly variable (range, 26 to 71 hours). There was a trend toward higher median area under the concentration-versus-time curve (AUC) in those children with musculoskeletal (72 μmol/L h; P = .054) or neurologic toxicity (54 μmol/L h; P = .062) versus those without toxicity (30 μmol/L h). Toxicity was not significantly correlated with dosage. Conclusion: We conclude that paclitaxel distribution and elimination are saturable, and that estimates of paclitaxel systemic exposure correlate better with toxicity than does dosage.
引用
收藏
页码:532 / 538
页数:7
相关论文
共 26 条
[1]   A PHASE-I TRIAL OF TAXOL GIVEN BY A 6-HOUR INTRAVENOUS-INFUSION [J].
BROWN, T ;
HAVLIN, K ;
WEISS, G ;
CAGNOLA, J ;
KOELLER, J ;
KUHN, J ;
RIZZO, J ;
CRAIG, J ;
PHILLIPS, J ;
VONHOFF, D .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (07) :1261-1267
[2]  
EINZIG AI, 1991, INVEST NEW DRUG, V9, P59
[3]   PHASE-II STUDY AND LONG-TERM FOLLOW-UP OF PATIENTS TREATED WITH TAXOL FOR ADVANCED OVARIAN ADENOCARCINOMA [J].
EINZIG, AI ;
WIERNIK, PH ;
SASLOFF, J ;
RUNOWICZ, CD ;
GOLDBERG, GL .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (11) :1748-1753
[4]   CONCEPT OF MAXIMUM TOLERATED SYSTEMIC EXPOSURE AND ITS APPLICATION TO PHASE-I-II STUDIES OF ANTICANCER DRUGS [J].
EVANS, WE ;
RODMAN, JH ;
RELLING, MV ;
CROM, WR ;
RIVERA, GK ;
PRATT, CB ;
CRIST, WM .
MEDICAL AND PEDIATRIC ONCOLOGY, 1991, 19 (03) :153-159
[5]   PHARMACOKINETICS OF CAPACITY-LIMITED TISSUE DISTRIBUTION OF METHICILLIN IN RABBITS [J].
GENGO, FM ;
SCHENTAG, JJ ;
JUSKO, WJ .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1984, 73 (07) :867-873
[6]  
GIBALDI M, 1982, PHARMACOKINETICS, P271
[7]   PHASE-II TRIAL OF TAXOL, AN ACTIVE-DRUG IN THE TREATMENT OF METASTATIC BREAST-CANCER [J].
HOLMES, FA ;
WALTERS, RS ;
THERIAULT, RL ;
FORMAN, AD ;
NEWTON, LK ;
RABER, MN ;
BUZDAR, AU ;
FRYE, DK ;
HORTOBAGYI, GN .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (24) :1797-1805
[8]   PHASE-I TRIAL OF PACLITAXEL IN CHILDREN WITH REFRACTORY SOLID TUMORS - A PEDIATRIC-ONCOLOGY-GROUP STUDY [J].
HURWITZ, CA ;
RELLING, MV ;
WEITMAN, SD ;
RAVINDRANATH, Y ;
VIETTI, TJ ;
STROTHER, DR ;
RAGAB, AH ;
PRATT, CB .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (12) :2324-2329
[9]  
LEGHA SS, 1990, CANCER, V65, P2478, DOI 10.1002/1097-0142(19900601)65:11<2478::AID-CNCR2820651114>3.0.CO
[10]  
2-S